ÂÜÀòÂÒÂ×

Rebeca Romero Aburto Ph.D. is an accomplished professional in clinical development and research with extensive experience in oncology and nanotechnology. Currently serving as the Associate Director of Clinical Development at Azurity Pharmaceuticals since July 2023, Rebeca previously held leadership roles such as Director of Clinical Development Scientists at Mirati Therapeutics and Executive Alliance Manager at Nanobiotix, where significant contributions were made to the alliance with MD Anderson and the development of innovative therapeutic approaches. Rebeca's background includes a Clinical Research Scientist position at MD Anderson Cancer Center, where preclinical research proposals in immunotherapy were successfully produced, alongside postdoctoral work focusing on nanotechnology for cancer imaging. Educational credentials include a Ph.D. in Material Science Engineering, a Master's degree in Bioengineering, and a Bachelor's degree in Biotechnology Engineering and Bioprocesses from prestigious institutions.